Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
- None.
- None.
A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231220102589/en/
Chris Lewis
Vice President, Investor Relations & Corporate Affairs
(949) 481-0510
clewis@glaukos.com
Source: Glaukos Corporation
FAQ
What is the company name and ticker symbol for the ophthalmic medical technology and pharmaceutical company participating in the 42nd Annual J.P. Morgan Healthcare Conference?
When is Glaukos Corporation scheduled to participate in the 42nd Annual J.P. Morgan Healthcare Conference?
Where can I find the live and archived webcast for the 42nd Annual J.P. Morgan Healthcare Conference participation by Glaukos Corporation?
